Abstract:Targeted Protein Degradation (TPD) is a novel therapeutic modality that uses heterobifunctional small molecules to redirect the cellular machinery responsible for protein degradation and cellular homeostasis, the ubiquitin-proteasome system (UPS), toward specific disease-causing proteins through spatial proximity with the use of affinity rather than occupancy-based catalysis, delivering a potentially transformative new way to treat disease. To realize on the promise of this disease-agnostic technology, we have taken a unique approach to target selection, where we focus on targets that are either undrugged or inadequately drugged within key signaling pathways with clear clinical validation and validation through human genetics/causal biology, and where TPD is the best or the only solution - defining a clear path to early differentiation from existing technologies and agents. Additionally, our comprehensive drug discovery engine utilizes computational tools, fit-for-purpose technologies, and quantitative translational models to design potent and selective degraders and drive consistent fidelity of translation of safety, pharmacokinetics (PK), pharmacodynamics (PD), and early efficacy from preclinical models to patients, as observed across all our clinical programs. Within oncology, TPD has the potential to redefine treatment paradigms given the existence of numerous clinically validated targets coupled with the limitations of existing cancer therapies in key areas such as druggability, selectivity, resistance, potency, and durability. Here, we share vignettes that highlight the advantage of TPD over other technologies and strong preclinical to clinical translation from our first-in-class oncology programs. KT-333 is a potent, highly selective, heterobifunctional small molecule protein degrader of signal transducer and activator of transcription 3 (STAT3), a traditionally undrugged transcription factor recognized as a key component of the Janus Kinase (JAK)-STAT signaling pathway with both tumor cell intrinsic and tumor cell extrinsic effects on the tumor microenvironment. Although multiple drugs have been approved that target upstream effectors signaling through STAT3, no known drugs selectively block STAT3 broadly across all relevant cell types or address both phosphorylation-dependent and -independent functions of STAT3. For these reasons, we believe that STAT3 degraders may provide a solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies. In preclinical studies, KT-333 has shown durable single agent antitumor activity across multiple liquid and solid tumor models. Additionally, degradation of STAT3 has both antiproliferative and proapoptotic effects on tumor cells as well as immunomodulatory effects on tumor cells and the tumor microenvironment. This leads to robust anti-tumor activity in preclinical models of STAT3-dependent T-cell lymphomas and syngeneic models of solid tumors combined with immunotherapies such as checkpoint blockade - which only work in a small percentage of patients. Interim data from the Phase 1a clinical trial demonstrated early signs of antitumor activity at doses that were generally well-tolerated and associated with substantial STAT3 knockdown in blood and tumor. Preclinical to clinical translation showed strong responses in both cutaneous T-cell lymphoma (CTCL) and in Hodgkin's lymphoma as well as induction of an Interferon (IFN)-ƴ response in tumor and blood that preclinically was shown to enhance the response of solid tumors to anti-PD-1 drugs. We believe this supports KT-333's potential to address both hematological malignancies as a single agent and solid tumors as a potential novel combination therapy with anti-PD-1 or other targeted therapies. KT-253 is a highly potent heterobifunctional degrader of the murine double minute 2 (MDM2) oncoprotein, a key E3 ligase that modulates the most common tumor suppressor, p53. p53 is a transcription factor that regulates cellular responses to stress and guides cell fate decisions such as cell cycle arrest, DNA repair, senescence, and apoptosis. Loss of p53 function leads to inability of cells to respond to cellular stressors such as DNA damage and leads to genetic instability, a hallmark of cancer. Notably, p53 remains intact in close to 50% of cancers. While small molecule inhibitors have been developed to stabilize and upregulate p53 expression, they have been found to induce a feedback loop that increases MDM2 protein levels, which can repress p53 and therefore limit their efficacy. In preclinical studies, KT-253, unlike small molecule inhibitors of MDM2, has shown the ability to overcome the MDM2 feedback loop and thereby robustly activate the p53 pathway, even with brief exposures. KT-253 more effectively upregulates and activates p53 in tumors in vivo compared to small molecule MDM2 inhibitors, and this tr -Abstract Truncated-

Discovery of a Selective TC-PTP Degrader for Cancer Immunotherapy

Abstract 4505: Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy

Discovery of HDM2010, a highly potent PTPN2 inhibitor for immunotherapy.

Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP

A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy

Abstract 4038: Discovery of potent and selective inhibitors of the protein tyrosine phosphatases PTPN2 and PTPN1 to trigger anti-tumor immunity through sensitization of tumor cells and activation of immune cells

Targeting PTPs with small molecule inhibitors in cancer treatment

Abstract SY12-01: Targeting validated but un-drugged oncogenes with small molecule protein degraders

Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes

Abstract 4514: Discovery of potent and orally bioavailable degraders of HPK1 based on a novel HPK1 binder

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Targeted protein degrader development for cancer: advances, challenges, and opportunities

Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex

Abstract B003: Validating PTPN22 as a cancer-agnostic immunotherapeutic target

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Degraders Upgraded: The Rise of PROTACs in Haematological Malignancies

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies Against Cancer

Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders